RecruitMe Clinical Trial

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)
Study of CPI-0610 in Patients with Myelofibrosis
Sponsor:Constellation Pharmaceuticals
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAR8502
U.S. Government ID:NCT02158858
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

We are doing this study to find out if an investigational drug called CPI-0610 can help with myelofibrosis. An investigational drug is a drug that is not approved for sale in the United States by the Food and Drug Administration (FDA). This study has two groups (arms) one group of patients will be treated with CPI-0610 alone (monotherapy arm) and the other group of patients will be treated with CPI-0610 in combination with ruxolitinib (combination arm).

Do You Qualify?
Are you 18 years or older?YesNo
Do you have myelofibrosis (MF)?YesNo
Submit
Cancel
Investigator
Mark Heaney, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162